Keryx Biopharmaceuticals, Inc. Securities Litigation
On or around 10/16/2018 (Ongoing date of last review)
Filing Date: October 16, 2018
According to the Complaint, Keryx Biopharmaceuticals, Inc. ("Keryx" or the Company) is a commercial stage biopharmaceutical company focused on bringing innovative medicines to people with kidney disease.
On June 28, 2018, Keryx and Akebia Therapeutics, Inc. entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which Keryx will become a wholly owned subsidiary of Akebia (the “Proposed Transaction”). Also on June 28, 2018, Keryx and Akebia issued a joint press release announcing the Proposed Transaction.
The Complaint alleges that on October 1, 2018, the Defendants filed a materially incomplete and misleading Proxy with the SEC and disseminated it to Keryx shareholders. The Proxy solicits the Company’s shareholders to vote in favor of the Proposed Transaction. The Complaint alleges that the Proxy misrepresents or omits material information that is necessary for the Company’s shareholders to make an informed voting decision in connection with the Proposed Transaction.
Company & Securities Information
Defendant: Keryx Biopharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: KERX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Gregory Corwin, et al. v. Keryx Biopharmaceuticals, Inc., et al.
COURT: D. Delaware
DOCKET #: 18-CV-01589
JUDGE: Hon. Leonard P. Stark
DATE FILED: 10/16/2018
CLASS PERIOD START: 06/28/2018
CLASS PERIOD END: 10/16/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Cooch & Taylor, P.A. The Brandywine Building; 1000 West Street, 10th Floor, Cooch & Taylor, P.A., DE 19801 302.984.3800 302.984.3939 ·
Monteverde & Associates PC 350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118 (212) 971-1341 ·
First Identified Complaint (FIC) Filings:
Complaint - Class Action for Violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available